FLAG’s President and Chief Executive Officer (CEO) Frank Sorgi, Ph.D., will discuss FLAG’s two platforms and its application in orphan oncology, specifically glioblastoma multiforme (GBM).Read More
The North Carolina Biotechnology Center announced a $500,000 Strategic Growth Loan to FLAG Therapeutics. The Strategic Growth Loan (SLG) is designed to help North Carolina life science product companies reach specific and meaningful milestones that will enable them to obtain further funding from investors and/or to commercialize their products. The award supports an Investigational New Drug filing with the U.S. Food and Drug Administration and completion of a Phase 1 safety study of a novel small molecule for treating glioblastoma, a malignant brain tumor with an extremely poor prognosis.Read More
FLAG Therapeutics awarded $1,500,000 Phase II SBIR - Development of Novel Targeted Chemotherapeutics for the Treatment of Malignant Pleural MesotheliomaRead More
University’s Largest Licensing Agreement— with Alumnus— Puts Anti-Cancer Compounds on Path to Commercialization
The largest licensing agreement in Duquesne University’s history brings the fruits of Dr. Aleem Gangjee’s career-long fight against cancer all the closer to commercialization.
“This is a unique opportunity for one of our researchers to join forces with an alumnus who can further his research efforts and attempt to bring these compounds to market,” says Pharmacy Dean J. Douglas Bricker.Read More
FLAG Therapeutics and Duquesne University Announce Exclusive Worldwide Licensing Agreement for Novel, Dual-action Targeted Oncology Compounds
Agreement encompasses a broad IP estate and library of anti-cancer compounds engineered for improved efficacy and tolerabilityRead More